Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 5/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442094 | 0.84 | CYP2A6 (0.34) | ALDH1A1MAOBKDM4EMAPTMAOA | |
| SCHEMBL2472169 | 0.83 | TAAR1 (0.38) | IDO1ALDH1A1MAOBKDM4ETAAR1 | |
| SCHEMBL6421635 | 0.82 | APP (0.44) | IDO1ALDH1A1APPRXRARXRB | |
| SCHEMBL5208873 | 0.82 | MAOB (0.37) | IDO1ALDH1A1APPMAOBKDM4E | |
| SCHEMBL9366824 | 0.81 | IDO1 (0.48) | IDO1ALDH1A1APPMAOBRXRA | |
| SCHEMBL722683 | 0.80 | IDO1 (0.49) | IDO1ALDH1A1MAOBTAAR1MAOA | |
| SCHEMBL2469752 | 0.80 | TAAR1 (0.36) | IDO1TAAR1 | |
| SCHEMBL21493100 | 0.79 | KMT2A (0.31) | ALDH1A1 | |
| SCHEMBL8710528 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MAOBMAPTHPGDMAOA | |
| SCHEMBL21493142 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507484-B2 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-1817301-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| WO-2003099786-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| EP-0663393-B1 | 3-Amino/hydroxy-4- 4-benzoylphenylcarboxylamino/oxy -azepanes and their homologies as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| US-5583222-A | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0663393-A1 | Novel 3-amino/hydroxy-4- 4-benzoylphenylcarboxylamino/oxy -azepanes and their homologies as protein kinase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1995-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | IDO1 3036/4885ALDH1A1 1737/4885APP 752/4885 |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | IDO1 3036/4885ALDH1A1 1737/4885APP 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.